Assessing the Health and Economic Outcomes of a 9-Valent HPV Vaccination Program in the United Kingdom
# Background The United Kingdom (UK) switched from using the 4-valent human papillomavirus (HPV) vaccine (Gardasil®) to the 9-valent vaccine (Gardasil 9®) in 2021. # Objective To estimate and compare the health and economic outcomes of 2 HPV vaccination programs in the UK targeting girls and boys a...
Saved in:
| Main Authors: | Kwame Owusu-Edusei, Cody Palmer, Olga Ovcinnikova, Giampiero Favato, Vincent Daniels |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Columbia Data Analytics, LLC
2022-06-01
|
| Series: | Journal of Health Economics and Outcomes Research |
| Online Access: | https://doi.org/10.36469/001c.34721 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Cost-Effectiveness Analysis of the Use of V116, a 21-Valent Pneumococcal Conjugate Vaccine, in Vaccine-Naïve Adults Aged ≥ 65 Years in the United States
by: Zinan Yi, et al.
Published: (2024-11-01) -
Post-marketing study design to evaluate the effectiveness of the 9-valent and 4-valent HPV vaccines on serious HPV-related cervical disease in China
by: Yu Yang, et al.
Published: (2024-12-01) -
A survey of potential acceptance of 9-valent HPV vaccine among Chinese male college students
by: Shu Jia, et al.
Published: (2023-12-01) -
Reduced risk of CIN2+ recurrence in women immunized with a 9-valent HPV vaccine post-excision: Retrospective cohort study
by: Vladimír Dvořák, et al.
Published: (2024-12-01) -
Acceptability of human papillomavirus vaccination in the United Kingdom: a systematic review of the literature on uptake of, and barriers and facilitators to HPV vaccination
by: Anna Karakusevic, et al.
Published: (2024-12-01)